Jones R E, Wegrzyn R J, Patrick D R, Balishin N L, Vuocolo G A, Riemen M W, Defeo-Jones D, Garsky V M, Heimbrook D C, Oliff A
Department of Cancer Research, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
J Biol Chem. 1990 Aug 5;265(22):12782-5.
Complex formation between the human papilloma virus type-16 E7 protein (HPV-16 E7) and the retinoblastoma suppressor protein (pRB) is believed to be important in the process of cellular transformation that leads to cervical carcinoma. Utilizing an in vitro solution assay as well as a plate binding assay that measures the association between HPV-16 E7 and pRB proteins, we have examined a series of synthetic HPV-16 E7 peptides. HPV-16 E7 peptides which lie between amino acid residues 14 and 32 were found to be potent inhibitors of E7/pRB binding. The minimal peptide structure that possessed full antagonist activity was N-acetyl-E7-(21-29)-peptide amide. This peptide inhibited 100% of E7/pRB binding and exhibited an IC50 of 40 nM in the plate binding assay. A purified beta-galactosidase-E7 fusion protein exhibited an IC50 of 2 nM in the same assay. These results suggest that other regions of the E7 molecule in addition to amino acids 21-29 may contributed to E7/pRB interaction. Analysis of E7-(20-29)-peptides containing single amino acid substitutions suggests that Cys24, Tyr23, Tyr25, Asp21, and Glu26 are important residues for maintaining maximal antagonist activity. This series of peptides should prove useful in analyzing the biological consequences of E7/pRB binding in HPV-infected cells.
人乳头瘤病毒16型E7蛋白(HPV - 16 E7)与视网膜母细胞瘤抑制蛋白(pRB)之间的复合物形成被认为在导致宫颈癌的细胞转化过程中起着重要作用。利用体外溶液测定法以及测量HPV - 16 E7与pRB蛋白之间结合的平板结合测定法,我们检测了一系列合成的HPV - 16 E7肽。发现位于氨基酸残基14至32之间的HPV - 16 E7肽是E7/pRB结合的有效抑制剂。具有完全拮抗活性的最小肽结构是N - 乙酰 - E7 -(21 - 29)-肽酰胺。该肽在平板结合测定中抑制了100%的E7/pRB结合,IC50为40 nM。在相同测定中,纯化的β - 半乳糖苷酶 - E7融合蛋白的IC50为2 nM。这些结果表明,除了氨基酸21 - 29之外,E7分子的其他区域可能也有助于E7/pRB相互作用。对含有单个氨基酸取代的E7 -(20 - 29)-肽的分析表明,Cys24、Tyr23、Tyr25、Asp21和Glu26是维持最大拮抗活性的重要残基。这一系列肽应有助于分析HPV感染细胞中E7/pRB结合的生物学后果。